


HYDAMTIQ

Cat. No.:	HY-155458
CAS No.:	1201832-32-7
Molecular Formula:	C ₁₄ H ₁₄ N ₂ O ₂ S
Molecular Weight:	274.34
Target:	PARP
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HYDAMTIQ is a PARP-1/2 inhibitor (IC ₅₀ : 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more ^[1] .
IC ₅₀ & Target	PARP-1/2 ^[1]

REFERENCES

[1]. Filippini P et al. Continuous Flow Synthesis of the PARP-1/2 Inhibitor HYDAMTIQ: Synthetic Strategy, Optimization, and Green Metrics Evaluation[J]. Organic Process Research & Development, 2023.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA